HeartPort's Quiet Exit
Executive Summary
In the mid 1990's, many industry executives believed HeartPort Inc. was going to lead a revolution in cardiac minimally-invasive surgery. But the minimally-invasive cardiac surgery market has evolved in a different path than anyone, including many companies other than HeartPort, envisioned a decade ago. In the end, the broader vision of a transforming technology failed to materialize for HeartPort. Ethicon recently purchased the company for $81 million.
You may also be interested in...
HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology
Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?
HeartFlow: Disrupting The Diagnostic Paradigm In Cardiology
Most current cardiac diagnostic imaging tests are highly inexact, relying heavily on clinicians' observations. HeartFlow is adapting advanced computer modeling to cardiology to produce a precise, predictive, noninvasive diagnostic that doubles as a treatment planning tool. The test could eliminate unnecessary procedures for patients and save the system money, but is that what interventionalists want?
Cardica: Rebuilding the Cardiac Surgery Market
The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.